Clinical Trial Update: WR 279,396 for the Treatment of Cutaneous Leishmaniasis [Phase 2]

View source ↗

Summary

This is an update on a Phase 2 trial evaluating WR 279,396 for cutaneous leishmaniasis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cutaneous Leishmaniasis

Drugs mentioned

• WR 279,396

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Cutaneous Leishmaniasis | Phase 2 | Status: COMPLETED